Clinical Trial

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection.
Protocol Amendment History 1 change
notable Trial sites expanded: 44 -> 48 locations 2026-06-16
Trial Details
NCT Number NCT07200908
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions Chronic Hepatitis D Infection
Enrollment 172 participants
Start Date 2025-08-27
Primary Completion 2027-06-30 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15